Interview: Carl Firth, CEO, ASLAN Pharmaceuticals, Taiwan
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
ASLAN is an Asia enabled pharmaceutical company that develops novel medicines for global markets.
1. ASLAN inlicenses preclinical drugs that are up to 6-12 months from the clinic
2. ASLAN uses its own financial resources and high quality CRO facilities to perform preclinical, Phase 1 and 2 studies on the partnered compounds
3. ASLAN gets Proof of Concept (PoC) for the partnered compounds in Asia
4. ASLAN outlicenses PoC compounds back to partner for global development and launch
Walsin Xinyi Building, 11/F
No. 1, Songzhi Road
Taipei 11047, Taiwan 11047
Tel: +886 2 8729 2180
Fax: +886 2 8729 2333
http://www.aslanpharma.com/index.html
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development…
Calvin Tsai and Jack Wu talk about their two-pronged international approach through pharmaceuticals and nutricare. The head of the nutricare business elaborates on the challenge of introducing milk products to…
A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not…
Charles Lin discusses the impact of investment in R&D on Lotus’s product line, and how this has shaped the competitive value of the company over the last decade, as well…
In Taiwan, GSK recently signed Memorandum of Understanding with the National Research Program of Biopharmaceuticals (NRPB), building on research partnerships in Taiwan that include a 2007 agreement with National Taiwan…
Dr. Wen, can you please explain the vision behind Mycenax, and the areas in which you are currently focused? Here at Mycenax, our vision is from bench to better life…
Dr. Karen Wen of Mycenax likened her company to a “kitchen.” Would you say the same of JHL? Racho Jordanov (RJ): We might…
The latest details regarding Article 46, a key piece of legislation attached to the second-generation health insurance reform, were announced this week. What are the key points to take away…
Phytohealth is a trailbalzer in the Taiwanese biotech industry: the first publically-listed biopharma company in the country, and the first company to receive NDA approval for a Botanical New Drug.…
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
Mr. Fang-Yue Lin was a Department of Health Minister before becoming Superintendent of TVGH just 7 short months ago. He shares with us his Insight to the reform of the…
Alex Ho has more than 15 years of significant pharmaceutical industry expertise, spanning across sales, marketing and product management in multinational companies. These companies include Novartis, Janssen, L’Oreal, GSK and…
See our Cookie Privacy Policy Here